Pharmacy Podcast Network

Alan McGill is a Senior Supervisory Special Agent with the Pennsylvania Office of Attorney General and currently assigned to the Office of Public Engagement. Agent McGill has been a professional investigator for over 35 years with 27 years in law enforcement. He served nearly 20 years at the Bureaus of Narcotics Investigation and Drug Control with his previous assignment being a Street Supervisor and Drug Diversion Unit Supervisor. He also served as an Undercover Narcotics Agent, Drug Task Force Coordinator, Drug Diversion Agent, Computer Voice Stress Analyst, PDMP BNI Statewide Supervisor, Clandestine Laboratory Enforcement Program member and an "A" and "B" Technician installing wiretap equipment. Although Agent McGill's undercover experience is extensive, he is best known as a subject matter expert in Drug Diversion and is court qualified as an expert. Agent McGill routinely conducts Drug Diversion presentations and trainings for practitioners and law enforcement in Pennsylvania. Agent McGill also conducts drug diversion lectures at over 25 university practitioner programs in Pennsylvania and is a national speaker on the subject. In addition to conducting training lectures, Agent McGill also authored an article published in The Keystone Veterinary Magazine on Drug Diversion in veterinary practices and he has hosted podcasts for the Office of Attorney General that can be found on the Pennsylvania Attorney General website. Agent McGill joined NASCSA (National Association of State Controlled Substance Authorities) in 2014 serving on various committees including co-chairing the Education Committee and chairing the Executive Committee. In 2021 he was elected President of NASCSA. He also created The NASCSA Podcast and is the current producer and host. Protecting patients from injury due to drug diversion | Viewpoint https://www.chiefhealthcareexecutive.com/view/protecting-patients-from-injury-due-to-drug-diversion-viewpoint Wolters Kluwer acquires U.S. AI-enabled drug diversion detection software Technology leader seeks to help tackle growing drug diversion challenge in the U.S. https://www.businesswire.com/news/home/20230607005593/en/Wolters-Kluwer-acquires-U.S.-AI-enabled-drug-diversion-detection-software  NASCSA | National Association of State Controlled Substances Authorities https://www.nascsa.org/podcasts

In this episode Colby reviews his experiences at the MAPS conference in Denver, we review a couple of topics we missed around LSD and MDMA, and introduce psilocybin!   References: Gotvaldova K, et al. "Extensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids". International Journal of Molecular Sciences. 2023 (22): 14068. Halpern J, Roth BL "Hallucinogens and dissociative agents naturally growing in the United States". Pharmacology & Therapeutics. 2004; 102 (2): 131–8. Huberman A. The science of MDMA and its therapeutic uses: benefits and risks. Huberman Labs (podcast). 12 Jun 2023 Pollan M. How to change your mind: the new science of psychedelics. Penguin Press. 2019 Sumner R, et al. Microdosed LSD: Dose day outcomes from a home-administered randomized controlled trial. 2023. Unpublished (information from poster presentation at MAPS conference) Woolley DW, Campbell NK (1962). "Serotonin-like and antiserotonin properties of psilocybin and psilocin". Science. 3518. 136 (3518): 777–8 Vizeli P, et al. Genetic influence of Cyp2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis. Scientific Reports. 2021(11); 10851.

Pamela Spence EY Global Health Sciences and Wellness Industry Leader  Organizations have the tools to deliver a better personalized health experience, but the ecosystem needs to collaborate to build this future. Three questions to ask How can placing bigger bets, and making strategic investments that go beyond pilot initiatives, achieve transformation at scale? How do organizations collaborate to share risk, data and rewards and realize a better future? How do we move from a slowly digitizing world to connected care and ultimately to a smart health system? References: EY survey: 42% of global health consumers rate access to care as below average https://www.ey.com/en_gl/news/2023/06/ey-survey-42-of-global-health-consumers-rate-access-to-care-as-below-average How innovation can unlock the power of data to deliver value-based care https://www.ey.com/en_gl/life-sciences/how-innovation-can-unlock-the-value-of-data-to-deliver-value-based-care?linkId=206400904  New boost

On "This Week in Pharmacy" Todd Eury talks with the leading Digital Health Pharmacist in New Zealand Katrina Azer about the rising useage of technology as part of treatment plans in pharmacy care. Next, a special conversation with Community Pharmacy Business Coach of the Coaches, Patti Mara --who came from the PDS strategy team helping pharmacy leaders like Lisa Faast launch successful enterprises.

To claim CE credit for this activity, please follow this link: www.pharmacytimes.org/atopic-derm-podcast-630 Pharmacy Times Continuing Education™ (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-system pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multispecialty  education. Educational Objectives Review patient barriers that impact optimal treatment of patients with atopic dermatitis (AD) who are seeking OTC care List strategies to individualize patient care and improve recommendations for AD Moderator: Mary Bridgeman, PharmD, BCPS, BCGP Clinical Professor Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey Piscataway, New Jersey   Internal Medicine Clinical Pharmacist Robert Wood Johnson University Hospital New Brunswick, New Jersey   Faculty & Caregiver: Ashley Ellis, PharmD, MBA, CDECS ImPAcT Director & Assistant Professor The University of Tennessee Health Science Center Department of Clinical Pharmacy and Translation Science College of Pharmacy Memphis, Tennessee   Mary Bridgeman, PharmD, BCPS, BCGP, has no financial relationships with commercial interests to disclose. Ashley Ellis, PharmD, MBA, CDECS, has the following financial relationships with commercial interests to disclose: Grant/Research Support: Researcher AHRQ “Tennessee Heart Health Network” funding in form of salary release dollars Consultant: Global Parents for Eczema Research, Continuing Education Alliance, McGraw Hill   Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity numbers 0290-0000-23-268-H01-P and 0290-0000-23-268-H01-T. The activity is available for CE credit through June 30, 2024. This activity is supported by an educational grant from CeraVe and La Roche-Posay. Brought to you in partnership with the National Eczema Association.

https://surescripts.com/news-center/press-releases/detail/surescripts-names-frank-harvey-as-new-ceo-to-lead-company-through-continued-growth-and-new-opportunities-to-impact-healthcare ARLINGTON, Va. – June 6, 2022 – Surescripts, the nation's leading health information network, has appointed Frank Harvey as Chief Executive Officer, effective June 27. Harvey succeeds Tom Skelton, who previously announced his decision to retire. Harvey is a pharmacist and an experienced chief executive and investor and has held numerous senior leadership roles during his more than 35-year career in the healthcare technology, pharmacy and pharmaceutical sectors. Harvey joins Surescripts from ATLS Investments, LLC. where he led private equity investing in healthcare technology companies. Previously, Harvey served as Chief Executive Officer of Mirixa Corporation and Liberty Medical Supply, Inc. “It’s been a pleasure to work closely with Tom over the past eight years, and we appreciate the many successes that Surescripts achieved under his leadership,” explained Steven Miller, MD, Co-Chair of Surescripts’ Board of Directors. “We are now poised for continued growth and new opportunities with Frank’s leadership at this incredible time in healthcare.” “Frank is a results-oriented leader with strong operational skills, and extensive experience growing healthcare businesses,” said Douglas Hoey, Co-Chair of Surescripts’ Board of Directors. “Frank combines his unique perspective and depth of experience with a passion for improving the lives of patients and evolving the healthcare system.” “I’m honored to join Surescripts at such a critical time, and I look forward to working with the team to realize the enormous potential we have to change healthcare,” Harvey shared. “I’m committed to what we do as a company and the new products and services we will bring to market that I believe will have a significant impact on the healthcare system as a whole.”

We thought it would be beneficial to have a brief introduction to the concept of acadmic detailing (AD) and the evidence that supports AD. We also would like to briefly discuss our group (IL ADVANCE). We would introduce the structure of an AD visit leading into the specific opioid safety program for pharmacists. After identifying our topics we thought we could get into more detail about a couple, specifically special populations and OUD. We then would move on to the benefits of AD for the community pharmacist. We could then get into more detail about the IL ADVANCE team and the process for developing content.  Next would be conclusions and wrap up.

Debbie Marcello - host of Happier at Home PRN and Todd Eury, CEO of the Pharmacy Podcast Network welcome DiversifyRx founder Lisa Fasst, PharmD.  Lisa is on a mission to save independent pharmacies. Every pharmacy owner deserves to have a thriving, profitable pharmacy. Lisa became a pharmacy owner for the first time in 2005. She has been helping pharmacy owners improve their profitability and diversify their revenue streams since 2012. Lisa knows what it takes to be a pharmacy badass and started DiversifyRx, Pharmacy Badass University, and the Pharmacy Profit Summit to help every pharmacy owner create the pharmacy of their dreams.

In this podcast series, we answer some of the most frequently asked questions we’ve received from the public.

Continuing advances in cell and gene therapy (CGT) are transforming the pharmacy and point of care ecosystem. Recent launches of new CGTs have yielded mixed results on getting the right therapy to the right patients.  The CGTs pipeline and approvals are likely to rise dramatically in the near future. In 2024 alone, up to 21 cell therapy launches and as many as 31 gene therapy launches are on the horizon. Therefore, the launch readiness for these products should be effective so that the therapies can benefit as many patients as possible while ensuring a sufficient return on manufacturers’ investments. With so many new CGTs poised for commercialization, it’s imperative to consider innovative ways for a product launch that benefits CGTs patients. Ensuring that the market, the product, and the company itself are fully prepared for an effective launch will enable success.   Podcast Participants: Michelle Rice, CEO, Michelle Rice & Associates Kenneth Mankowski, DO, FACN, MS Neurologist Specialist, CNS & MS Institute Host:  Michael Baldzicki